Evaluation of COVID-19 protease and HIV inhibitors interactions
The epidemic of the novel coronavirus disease (COVID-19) that started in 2019 has evoked an urgent demand for finding new potential therapeutic agents. In this study, we performed a molecular docking of anti-HIV drugs to refine HIV protease inhibitors and nucleotide analogues to target COVID-19. The...
Saved in:
Main Authors: | Tran Linh, Tam Dao Ngoc Hien, Elhadad Heba, Hien Nguyen Minh, Huy Nguyen Tien |
---|---|
Format: | Article |
Language: | English |
Published: |
Sciendo
2022-03-01
|
Series: | Acta Pharmaceutica |
Subjects: | |
Online Access: | https://doi.org/10.2478/acph-2022-0010 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Promising inhibitors against main protease of SARS CoV-2 from medicinal plants: In silico identification
by: EBENEZER OLUWAKEMI, et al.
Published: (2022-06-01) -
Bicyclic peptide-enhanced covalent inhibitor of SARS-CoV-2 3CL protease
by: Qian Wang, et al.
Published: (2024-10-01) -
Triterpene esters from Uncaria rhynchophylla hooks as potent HIV-1 protease inhibitors and their molecular docking study
by: JiSuk Lee
Published: (2024-12-01) -
In silico binding role of flavonoids as SARS-CoV-2 main protease (Mpro) inhibitors: A dataset of molecular docking simulation-based high-throughput virtual screening (HTVS)Mendeley Data
by: Mariyam Eema, et al.
Published: (2025-04-01) -
Pretreatment with serine protease inhibitors impairs Leishmania amazonensis survival on macrophages
by: Patrícia de Almeida Machado, et al.
Published: (2025-01-01)